Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 54

1.

Functional characterization of FLT3 receptor signaling deregulation in acute myeloid leukemia by single cell network profiling (SCNP).

Rosen DB, Minden MD, Kornblau SM, Cohen A, Gayko U, Putta S, Woronicz J, Evensen E, Fantl WJ, Cesano A.

PLoS One. 2010 Oct 27;5(10):e13543. doi: 10.1371/journal.pone.0013543.

2.

Dasatinib induces complete remission in a patient with primary cerebral involvement of B-cell chronic lymphocytic leukemia failing chemotherapy.

Russwurm G, Heinsch M, Radkowski R, Erlemann R, Aul C, Haase S, Giagounidis A.

Blood. 2010 Oct 7;116(14):2617-8. doi: 10.1182/blood-2010-04-279786. No abstract available.

3.

Highly multiparametric analysis by mass cytometry.

Ornatsky O, Bandura D, Baranov V, Nitz M, Winnik MA, Tanner S.

J Immunol Methods. 2010 Sep 30;361(1-2):1-20. doi: 10.1016/j.jim.2010.07.002. Epub 2010 Jul 21. Review.

PMID:
20655312
4.

Revised map of the human progenitor hierarchy shows the origin of macrophages and dendritic cells in early lymphoid development.

Doulatov S, Notta F, Eppert K, Nguyen LT, Ohashi PS, Dick JE.

Nat Immunol. 2010 Jul;11(7):585-93. doi: 10.1038/ni.1889. Epub 2010 Jun 13.

PMID:
20543838
5.

B-cell signaling networks reveal a negative prognostic human lymphoma cell subset that emerges during tumor progression.

Irish JM, Myklebust JH, Alizadeh AA, Houot R, Sharman JP, Czerwinski DK, Nolan GP, Levy R.

Proc Natl Acad Sci U S A. 2010 Jul 20;107(29):12747-54. doi: 10.1073/pnas.1002057107. Epub 2010 Jun 11.

6.

Dynamic single-cell network profiles in acute myelogenous leukemia are associated with patient response to standard induction therapy.

Kornblau SM, Minden MD, Rosen DB, Putta S, Cohen A, Covey T, Spellmeyer DC, Fantl WJ, Gayko U, Cesano A.

Clin Cancer Res. 2010 Jul 15;16(14):3721-33. doi: 10.1158/1078-0432.CCR-10-0093. Epub 2010 Jun 4.

7.

Comparison of ATP-binding cassette transporter interactions with the tyrosine kinase inhibitors imatinib, nilotinib, and dasatinib.

Dohse M, Scharenberg C, Shukla S, Robey RW, Volkmann T, Deeken JF, Brendel C, Ambudkar SV, Neubauer A, Bates SE.

Drug Metab Dispos. 2010 Aug;38(8):1371-80. doi: 10.1124/dmd.109.031302. Epub 2010 Apr 27.

8.

Novel mutations in the inhibitory adaptor protein LNK drive JAK-STAT signaling in patients with myeloproliferative neoplasms.

Oh ST, Simonds EF, Jones C, Hale MB, Goltsev Y, Gibbs KD Jr, Merker JD, Zehnder JL, Nolan GP, Gotlib J.

Blood. 2010 Aug 12;116(6):988-92. doi: 10.1182/blood-2010-02-270108. Epub 2010 Apr 19.

9.

Evaluation of a 12-color flow cytometry panel to study lymphocyte, monocyte, and dendritic cell subsets in humans.

Autissier P, Soulas C, Burdo TH, Williams KC.

Cytometry A. 2010 May;77(5):410-9. doi: 10.1002/cyto.a.20859.

10.

Dasatinib.

Lindauer M, Hochhaus A.

Recent Results Cancer Res. 2010;184:83-102. doi: 10.1007/978-3-642-01222-8_7. Review.

PMID:
20072833
11.

Phenotypes of stem cells from diverse origin.

Tárnok A, Ulrich H, Bocsi J.

Cytometry A. 2010 Jan;77(1):6-10. doi: 10.1002/cyto.a.20844. Review.

12.

B cell signaling and fate decision.

Kurosaki T, Shinohara H, Baba Y.

Annu Rev Immunol. 2010;28:21-55. doi: 10.1146/annurev.immunol.021908.132541. Review.

PMID:
19827951
13.

Cell cycle-related cyclin b1 quantification.

Frisa PS, Jacobberger JW.

PLoS One. 2009 Sep 18;4(9):e7064. doi: 10.1371/journal.pone.0007064.

14.

Immunosuppression and atypical infections in CML patients treated with dasatinib at 140 mg daily.

Sillaber C, Herrmann H, Bennett K, Rix U, Baumgartner C, Böhm A, Herndlhofer S, Tschachler E, Superti-Furga G, Jäger U, Valent P.

Eur J Clin Invest. 2009 Dec;39(12):1098-109. doi: 10.1111/j.1365-2362.2009.02206.x. Epub 2009 Sep 9.

PMID:
19744184
15.

Mass cytometry: technique for real time single cell multitarget immunoassay based on inductively coupled plasma time-of-flight mass spectrometry.

Bandura DR, Baranov VI, Ornatsky OI, Antonov A, Kinach R, Lou X, Pavlov S, Vorobiev S, Dick JE, Tanner SD.

Anal Chem. 2009 Aug 15;81(16):6813-22. doi: 10.1021/ac901049w.

PMID:
19601617
16.

Tyrosine kinase inhibitor-induced platelet dysfunction in patients with chronic myeloid leukemia.

Quintás-Cardama A, Han X, Kantarjian H, Cortes J.

Blood. 2009 Jul 9;114(2):261-3. doi: 10.1182/blood-2008-09-180604. Epub 2009 May 4.

17.

Navigating the network: signaling cross-talk in hematopoietic cells.

Fraser ID, Germain RN.

Nat Immunol. 2009 Apr;10(4):327-31. doi: 10.1038/ni.1711. Epub 2009 Mar 19. Review.

18.

Cancer stem cells in solid tumors: an overview.

O'Brien CA, Kreso A, Dick JE.

Semin Radiat Oncol. 2009 Apr;19(2):71-7. doi: 10.1016/j.semradonc.2008.11.001. Review.

PMID:
19249644
19.

Homeostasis of naive and memory T cells.

Surh CD, Sprent J.

Immunity. 2008 Dec 19;29(6):848-62. doi: 10.1016/j.immuni.2008.11.002. Review.

20.

Translation of the Philadelphia chromosome into therapy for CML.

Druker BJ.

Blood. 2008 Dec 15;112(13):4808-17. doi: 10.1182/blood-2008-07-077958. Review.

Supplemental Content

Support Center